BC
CABA icon

Birchview Capital’s Cabaletta Bio CABA Stock Holding History

Birchview Capital’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,000
Closed -$47.2K – 70
2024
Q3 		$47.2K Hold
10,000
– – 0.04% 59
2024
Q2 		$74.8K Hold
10,000
– – 0.07% 55
2024
Q1 		$171K Hold
10,000
– – 0.14% 51
2023
Q4 		$227K Buy
+10,000
New +$168K 0.18% 50

Other funds holding CABA

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Birchview Capital's CABA Position: Q4 2024 in Review

Birchview Capital sold out of Cabaletta Bio (CABA) in Q4 2024, closing a stake of 10,000 shares — an estimated $47.2K sold.

Birchview Capital first reported a position in CABA in Q4 2023 and held it in 4 quarters. The position peaked at $227K in Q4 2023. 108 funds tracked by Wall St. Rank hold CABA as of Q4 2024.

  • Birchview Capital reported no remaining Cabaletta Bio position as of Q4 2024 after selling out during the quarter.
  • Birchview Capital sold 10,000 Cabaletta Bio shares in Q4 2024, an estimated $47.2K.
  • Birchview Capital first reported a position in Cabaletta Bio in Q4 2023 and held it in 4 quarters.
  • Birchview Capital's Cabaletta Bio position peaked at $227K in Q4 2023.
  • 108 funds tracked by Wall St. Rank held Cabaletta Bio as of Q4 2024.

Based on Birchview Capital's 13F filing for Q4 2024, filed 14 Feb 2025.